#AANAM – Vutrisiran Leads to Certain Benefits for Phase 3 Trial Patients

#AANAM – Vutrisiran Leads to Certain Benefits for Phase 3 Trial Patients

292464

#AANAM – Vutrisiran Leads to Certain Benefits for Phase 3 Trial Patients

Editor’s note: The FAP News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Vutrisiran, an investigational therapy for familial amyloid polyneuropathy (FAP), safely and effectively eased neurologic impairments and improved quality of life and walking abilities in adults with FAP, according to nine-month data from an ongoing Phase 3 trial. The experimental therapy, from Alnylam Pharmaceuticals, was able to…

You must be logged in to read/download the full post.